Scholar Rock to Present Clinical and Biomarker Data from the Phase 1 DRAGON Trial at the SITC 38th Annual Meeting

Poster presentations to include safety, efficacy, and biomarker data from Part A and B of the DRAGON trial in patients with advanced solid tumors treated with SRK-181


...

Related Keywords

Texas ,United States ,Jay Backstrom ,Timothy Yap ,Susan Henry ,San Diego Convention Center ,Exchange Commission ,University Of Texas Md Anderson Cancer Center ,Translational Sciences ,Twitter ,Department Of Investigational Cancer Therapeutics ,Linkedin ,Scholar Rock Inc ,Society For Immunotherapy Of Cancer ,Scholar Rock ,Annual Meeting ,San Diego ,Chief Executive Officer ,Establishing Proof ,Preliminary Biomarker Data ,Senior Director ,Exhibit Halls ,Medical Oncologist ,Associate Professor ,Investigational Cancer Therapeutics ,Securities Act ,Private Securities Litigation Reform Act ,Quarterly Report ,Markets ,